CTLA4 and lymphedema: With the clinical data suggesting that anti-CTLA4 can efficiently prevent lymphedema onset in patients with lymphadenectomy, we prompted the implementation of the treatment in the mouse-tail lymphedema model, to prospectively verify the outcome and investigate the pathomechanisms underlying the observed effect.